# US 2022/0009913 A1 · Small molecule inhibitors of galectin-3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009913 A1
- Document ID: US20220009913A1
- Status: Published application
- Kind: A1
- Application number: 17/299,325
- Filed: 2019-12-04
- Published: 2022-01-13
- Earliest claimed: 2018-12-06
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Jacob Swidorski; Brett R. Beno; David S. Yoon; Alicia Regueiro-Ren
- Web page: https://patentgrep.com/patent/US20220009913A1

## CPC

- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

## Claims

### Claim 1

A compound of formula I
where:
R1 is ((R3)(R4)N)carbonyl or Ar2;
R2 is —O-L1-O—, —OCON(R5)-L2-N(R5)C(O)O—, or —O-(L3)-CON(R5)-L2-N(R5)C(O)-(L3)-O—;
L1 is alkylene;
L2 is alkylene, or —CH2-Ph-CH2—;
or N(R5)-L2-N(R5) taken together is piperazinyl, or homopiperazinyl;
L3 is alkylene;
R3 is hydrogen, alkyl, cycloalkyl, benzyl, or halobenzyl;
R4 is hydrogen or alkyl;
or (R3)(R4)N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, and alkylcarbonyl;
R5 is hydrogen or alkyl;
R6 is hydrogen or alkyl;
R7 is hydrogen or alkyl;
or (R6)(R7)N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, and hydroxy;
R8 is hydrogen, alkyl, alkylcarbonyl, or alkylsulfonyl;
R9 is hydrogen or alkyl;
or (R8)(R9)N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, and alkylcarbonyl;
R10 is cyano, halo, alkoxy, or (R11)(R12)N;
R11 is hydrogen or alkyl;
R12 is hydrogen or alkyl;
or (R11)(R12)N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;
R13 is hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, or alkylsulfonyl;
R14 is hydrogen or alkyl;
or (R13)(R14)N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, and hydroxy;
R15 is hydrogen, alkyl, alkylcarbonyl, or alkylsulfonyl;
R16 is hydrogen or alkyl;
or (R15)(R16)N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, and alkylcarbonyl;
Ar1 is pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, phenyl, or indolyl, and is substituted with 0-3 substituents selected from alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (H2NCO)alkyl, (Ar3)alkyl, cycloalkyl, hydroxycycloalkyl, alkenyl, alkoxy, alkylthio, alkylsulfonyl, carboxy, alkoxycarbonyl, (alkylNH)carbonyl, (((R6)(R7)N)alkylNH)carbonyl, ((pyridinyl)alkylNH)carbonyl, (R8)(R9)N, and Ar3;
Ar2 is phenyl, pyridinyl, naphthyl, benzoxazolyl, benzothiazolyl, quinolinyl, or quinoxalinyl, and is substituted with 0-5 substituents selected from cyano, halo, alkyl, (R10)alkyl, haloalkyl, cycloalkyl, (R10)cycloalkyl, alkoxy, cycloalkoxy, haloalkoxy, and (R13)(R14)N; and
Ar3 is phenyl, naphthalinyl, biphenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, quinoxainyl, indolyl, indazolyl, benzimidazolyl, benzisoxazolyl, benzisothiazolyl, benzoxazolyl, benzothiazolyl, benzodioxolyl, dihydrobenzodioxinyl, dihydroquinolinonyl, or dihydrobenzothiophene-2,2-dioxide, and is substituted with 0-5 substituents selected from cyano, nitro, halo, alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, alkylthio, carboxy, alkoxycarbonyl, CONH2, and (R15)(R16)N;
or Ar3 is pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, or thiadiazolyl, and is substituted with 0-3 substituents selected from cyano, nitro, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, carboxy, alkoxycarbonyl, CONH2, and (R15)(R16)N;
or Ar3 is (alkylSO2)phenyl, (alkylSO2)(halo)phenyl, (aminoSO2)phenyl, (dialkylaminoSO2)phenyl, ((alkylNHSO2)alkyl)phenyl, (pyrrolyl)phenyl, (imidazolyl)phenyl, (oxazolyl)phenyl, (tetrazolyl)phenyl, ((pyridinyl)methyl)phenyl, phenoxyphenyl, (benzyloxy)phenyl, ((methyl)thiazolyl)phenyl, (thiazolyl)benzenesulfamido, ((methyl)thiadiazolyl)benzenesulfamido, (methyl)benzothiazolonyl, or fluoropyrazolopyrimidinyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1 where R1 is Ar2; Ar1 is triazolyl substituted with 0-3 substituents selected from alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (H2NCO)alkyl, (Ar3)alkyl, cycloalkyl, hydroxycycloalkyl, alkenyl, alkoxy, alkylthio, alkylsulfonyl, carboxy, alkoxycarbonyl, (alkylNH)carbonyl, (((R6)(R7)N)alkylNH)carbonyl, ((pyridinyl)alkylNH)carbonyl, (R8)(R9)N, and Ar3; Ar2 is phenyl or pyridinyl and is substituted with 0-5 substituents selected from cyano, halo, alkyl, (R10)alkyl, haloalkyl, cycloalkyl, (R10)cycloalkyl, alkoxy, cycloalkoxy, haloalkoxy, and (R13)(R14)N; and Ar3 is phenyl or benzothiazolyl and is substituted with 0-5 substituents selected from cyano, nitro, halo, alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, alkylthio, carboxy, alkoxycarbonyl, CONH2, and (R15)(R16)N; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound of claim 1 where R1 is Ar2; R2 is hydroxy; Ar1 is triazolyl substituted with 0-2 substituents selected from alkyl, haloalkyl, and Ar3; Ar2 is phenyl substituted with 0-5 halo substituents; and Ar3 is phenyl substituted with 0-5 substituents selected from halo, alkyl, haloalkyl, cycloalkyl, alkoxy, and haloalkoxy; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of claim 1 where R1 is Ar2.

### Claim 5 (depends on 1)

A compound of claim 1 where Ar1 is triazolyl substituted with 0-3 substituents selected from alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (H2NCO)alkyl, (Ar3)alkyl, cycloalkyl, hydroxycycloalkyl, alkenyl, alkoxy, alkylthio, alkylsulfonyl, carboxy, alkoxycarbonyl, (alkylNH)carbonyl, (((R6)(R7)N)alkylNH)carbonyl, ((pyridinyl)alkylNH)carbonyl, (R8)(R9)N, and Ar3.

### Claim 6 (depends on 1)

A compound of claim 1 where Ar1 is triazolyl substituted with 0-2 substituents selected from alkyl, haloalkyl, and Ar3.

### Claim 7 (depends on 1)

A compound of claim 1 where Ar2 is phenyl or pyridinyl and is substituted with 0-5 substituents selected from cyano, halo, alkyl, (R10)alkyl, haloalkyl, cycloalkyl, (R10)cycloalkyl, alkoxy, cycloalkoxy, haloalkoxy, and (R13)(R14)N.

### Claim 8 (depends on 1)

A compound of claim 1 where Ar2 is phenyl substituted with 0-5 halo substituents.

### Claim 9 (depends on 1)

A compound of claim 1 where Ar3 is phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.

### Claim 10 (depends on 1)

A composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method for use in treating fibrosis of organs (including liver, kidney, lung, heart and skin), liver diseases and conditions (including acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, non-alcoholic steatohepatitis (NASH), liver hypofunction, and hepatic blood flow disorder), cell proliferative diseases, cancers, and conditions (including solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL)) and invasive metastasis of cancer cell), inflammatory diseases and conditions (including psoriasis, nephropathy, and pneumonia), gastrointestinal tract diseases and conditions (including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and abnormal pancreatic secretion), renal diseases and conditions, urinary tract-associated diseases and conditions (including benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, and symptoms derived from diabetes), lower urinary tract diseases and conditions (including obstruction of lower urinary tract), inflammatory diseases and conditions of lower urinary tract (including dysuria and frequent urination), pancreatic diseases and conditions, abnormal angiogenesis-associated diseases and conditions (including arterial obstruction), scleroderma, brain-associated diseases and conditions (including cerebral infarction and cerebral hemorrhage), neuropathic pain and peripheral neuropathy, ocular diseases and conditions (including age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, and glaucoma filtration surgery scarring) comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need.

### Claim 13 (depends on 12)

The method of claim 12 where the disease or condition is renal fibrosis, pulmonary fibrosis, hepatic fibrosis, arterial fibrosis, or systemic sclerosis.
